BIOBADASER 3.0 registry analysis shows risk of incident cancer in patients with rheumatic diseases and previous malignancy did not differ between TNFi or other b/tsDMARDs. Exciting, real-world data. Abs 0267 #ACR22 @RheumNow https://t.co/vZIN3U0QED https://t.co/EM1xXOv0Yd
Links:
Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheuma…
http://ow.ly/JuKu50Luyya
12-11-2022
